Back to Screener

Dermata Therapeutics, Inc. Warrant (DRMAW)

Price$0.01
Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-44.88%
Price vs S&P 500 (4W)-27.91%
VGM Score24.87

All Metrics

Price vs S&P 500 (YTD)-52.98%
10-Day Avg Trading Volume0.01M
3-Month Avg Trading Volume0.01M
52-Week High$0.03
26-Week Price Return-31.00%
13-Week Price Return-36.11%
3-Month Return Std Dev195.37%
Year-to-Date Return-42.74%
5-Day Price Return0.73%
Month-to-Date Return-8.00%
Price vs S&P 500 (13W)-44.98%
Beta1.45x
52-Week Low$0.01
mGradeD
vgmGradeD
Show chart for

Industry Peers — Pharmaceuticals(550)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
DRMAWDermata Therapeutics, Inc. Warrant
D$0.01
LLYEli Lilly & Co.DBB$1082.20
JNJJohnson & JohnsonCCC$223.51
ABBVABBVIE INC.DCC$212.93
MRKMerck & Co., Inc.CCC$115.17
NVSNovartis AGCCC$145.68
AZNAstraZeneca PLCDBC$179.71
NVONovo-Nordisk A/SBBC$44.07
ABTAbbott LaboratoriesCCD$87.78
PFEPfizer Inc.BCC$25.63
TEVATeva Pharmaceutical Industries Limited American Depositary SharesCCC$34.64

About

Dermata Therapeutics develops over-the-counter dermatology products for acne, psoriasis, rosacea, and seborrheic dermatitis. The company is advancing a once-weekly acne treatment combining an OTC-approved active ingredient with its proprietary Spongilla delivery technology. Dermata intends to expand the Spongilla platform across multiple dermatologic and aesthetic applications, including intradermal botulinum toxin delivery.